#EULAR2023 #OP0052 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal purpose? Post-hoc analyses of 3 x RCTs showed predictors were: - Current/former renal involvement - high baseline proteinuria - hypoalbuminaemia - low C3 @RheumNow https://t.co/vylWCf0XNy

RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.

Beydon et al., french registry study 255000+ RA patients 2010-2020 Increase ⬆️ overall malignancy by 20% vs. general pop ⬆️lung 40%, ENT 40%, cervix 80%, prostate 8%, melanoma 37% Pancreatic cancer 10% less frequent in ♂ Breast 9% & Uterine body 23% less frequent in ♀

So can computers beat humans in predicting RA from pre-RA arthralgia MRIs? No, for now… but unsupervised they pick up the same culpable features we look for: bone marrow edema & tenosynovitis. Sometimes it’s nice when the machines tell us we’re right #EULAR2023 OP0002 @RheumNow https://t.co/71Zo2JyC8d

I swear it is muscle, Doctor! GLORIA trial substudy Pred 5 mg/day 2 years in RA pts >65yo: Weight gain 1kg vs. PBO, no increase or redistribution of fat mass but augmentation in lean mass 💪 Probably explained by better disease control (although NS in study, small sample size)

Mild correlation between fine motor hand skills and synovitis score grey scale and PD However no correlation w/ TJC68/SJC66 https://t.co/ryCs21KRcB

#EULAR2023 #OP0053 Baricitinib in non-renal #lupus were inconclusive. How about Renal #SLE?An RCT showed primary endpoint (=>50% reduction in proteinuria) was met more in Bari vs Cyclo at Wks12 & 24. Intriguing but need longer-term, composite endpoint and larger size! @RheumNow https://t.co/z3YJog6gTy

Loss of grip strength in PsA is NOT correlated w/ clinical parameters but US features US study of 100+ pts w/ Pso or PsA Strong correlation grip strength & grey scale tenosynovitis score (digit 2) r=-0.6 https://t.co/qClfMrhqhI OP0069 #EULAR23 @Rheumnow

• EULAR Abstract Archive

EULAR imaging recommendations in gout - ultrasound and DECT are recommended, double contour sign useful, by Peter Mandl, Abstr#0008 @RheumNow https://t.co/BNd1S3AJpB

EULAR PtoC management of targeted therapies in pts w/ IA & Hx cancer 1) If remission, initiate targeted therapy w/out delay 2) Prefer anti-cytokine bDMARDs if Hx solid cancer 3) B cell depleting therapy if Hx lymphoma 4) Use JAK inhibitors and abatacept with caution 🛑 https://t.co/cKhQVZwGh1

#EULAR2023 Could we predict renal flares in #lupus patients treated with Belimumab for non-renal purpose? Post-hoc analyses of 3 x RCTs showed predictors were: - Current/former renal involvement - high baseline proteinuria - hypoalbuminaemia - low C3 @RheumNow https://t.co/bBtBm1olcr

Belimumab in Lupus Nephritis Belimumab is a BLyS-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis. https://t.co/f2odJWlyR2 https://t.co/y5exJIFzht

• https://bit.ly/3OGnhHk

Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of autoimmune disease - no evidence of overall increase in conditions. Environmental and socioeconomic factors involved in the presentation of the conditions https://t.co/3jy9NoltkG

Prediction of RA early arthritis & clinically suspect arthralgia pts w/ AI analysis of MRIs scans: ✔️Feasible ✔️Accurate AUC 0.683 EA group AUC 0.727 CSA group ✔️Peformance = human experts ✚ Could identify new imaging biomarkers https://t.co/sVXw9A8NqZ OP0002 #EULAR23 @Rheumnow https://t.co/oq5RJApm9U

• EULAR Abstract Archive

🚨EULAR PtC clinical & imaging features suspicious for progression to PsA Main take home messages ⬇️⬇️ Obesity, Nail Disease, Extensive PsO, Arthralgia, US detected synovio-entheseal involvement/abnormalities in US = risks factors of developing PsA in PsO pts. @Rheumnow #EULAR23